# Mechanismen en actuele therapieën bij metabool syndroom

*geplaatst 2026-09-02 · Nierziekte · MedComm · doi 10.1002/mco2.70934 · https://hartvaat.nl/2026/09/01/mechanismen-en-actuele-therapieen-bij-metabool-syndroom/*

Dit narratieve overzicht beschrijft de onderliggende pathofysiologie van het metabool syndroom, met nadruk op insulineresistentie, chronische ontsteking, oxidatieve stress en de darm-vetweefsel-as. Voor de klinische praktijk worden de bewezen effecten van GLP-1-agonisten, SGLT2-remmers en RAAS-remmers besproken, naast opkomende strategieën zoals pre- en probiotica en leefstijlinterventies. Het artikel biedt cardiologen, internisten en huisartsen een gestructureerd overzicht van de huidige stand van zaken en mogelijke toekomstige richtingen voor de cardiometabole zorg.

## English: Metabolic Syndrome: From Mechanisms to Therapeutic Interventions.

This narrative review outlines the pathophysiology of metabolic syndrome, highlighting insulin resistance, chronic low-grade inflammation, oxidative stress, and the gut-adipose tissue axis. It evaluates current pharmacological standards, including GLP-1 receptor agonists, SGLT2 inhibitors, and RAAS blockers, while also discussing emerging interventions such as microbiome-targeted therapies and lifestyle modifications. The article provides a structured overview for clinicians managing cardiometabolic risk, bridging mechanistic insights with practical therapeutic options.

## Abstract (original, from the publication)

Metabolic syndrome describes a set of risk factors that can eventually lead to the occurrence of cardiovascular and cerebrovascular disease. Metabolic syndrome has emerged as a significant global health issue, associated with various metabolic diseases, including obesity, diabetes, hypertension, dyslipidemia, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and other metabolic disorders. Here, we summarize the intricate mechanisms including insulin resistance, chronic low-grade inflammation, oxidative stress, and epigenetic modifications, and how they contribute to the disease progression of metabolic syndrome. The gut-adipose tissue axis in the progression of metabolic syndrome is emphasized here, mainly involving adipocyte-derived extracellular vesicles and adipokines, as well as specific gut microbiota and their secreted factors, such as lipopolysaccharide, short-chain fatty acids, endocannabinoids, bile acids, aryl hydrocarbon receptor ligands, and tryptophan derivatives. Furthermore, the contemporary management for metabolic syndrome mainly includes some established pharmacological treatments such as GLP-1 receptor agonists, SGLT2 inhibitors, and RAAS inhibitors, as well as promising emerging therapies targeting the gut-adipose tissue axis such as lifestyle modifications, prebiotics, probiotics, synbiotic supplements, FMT, bariatric surgery, CB1R antagonists, and novel pharmacological agents. These strategies may pave the way for the development of effective treatments for metabolic diseases in future research.

Auteurs: Mengyao Yan, Qian Xiang

---
Bron: MedComm, https://doi.org/10.1002/mco2.70934. Bijgewerkt 2026-08-27T00:52:29Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.